India & Novo Nordisk
13 shared events · Importance 3 · Last updated Aug 01, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
Ergen Dashboard
Business
India: India becomes the seventh country to launch Awiqli, addressing its high diabetes burden and potentially improving public health outcomes.
Novo Nordisk: Novo Nordisk launched Awiqli, its once-weekly insulin, in India, enhancing its product portfolio and competitive edge in the diabetes market.
Jul 09, 2026 · 21 articles
Business
India: India is a key battleground for weight-loss drugs due to its large obesity population and is experiencing significant competition between Novo Nordisk and Eli Lilly and Company.
Novo Nordisk: Novo Nordisk cut the price of its weight-loss drug Semaglutide in India to compete with Eli Lilly and prepare for generic competition, aiming to increase market share and accessibility.
Nov 11, 2025 · 6 articles
Regulatory
India: India is the country where the approval was granted; the decision addresses a significant public health burden of fatty liver disease.
Novo Nordisk: Novo Nordisk is the drug manufacturer; the approval expands Wegovy's indication in India, potentially increasing sales and market share in the obesity and metabolic disease market.
Jul 17, 2026 · 13 articles
Tech
India: India is a key hub for global companies to develop and implement AI tools for advertising, positioning it as a center for innovation in this sector.
Novo Nordisk: Novo Nordisk's Bengaluru center is taking on a larger role in global drug launches, including preparatory work for its oral obesity pill in the United States. This indicates an increased strategic importance of its India operations.
May 26, 2026 · 12 articles
Tech
India: India is highlighted as a key hub for Global Capability Centres (GCCs) where multinational firms are increasingly deploying AI for various functions, showcasing its growing role in global innovation.
Novo Nordisk: Novo Nordisk>>> is deploying AI across critical parts of the drug launch process, including drafting regulatory documents and analyzing safety data, aligning with global efforts to save costs.
May 28, 2026 · 6 articles
Regulatory
India: India's regulatory body approved a new treatment for MASH, improving healthcare options for patients with liver disease.
Novo Nordisk: Novo Nordisk manufactures and supplies the innovator semaglutide used in Poviztra, benefiting from expanded indications in India.
Jul 20, 2026 · 8 articles
Business
India: India's regulatory action led Lilly to pause its campaign, highlighting cross-market regulatory risks.
Novo Nordisk: Novo launched the first once-weekly GLP-1 in China and is revamping its marketing under new president Cai Yan to better compete. Its market position is strong but faces increasing competition.
Aug 24, 2026 · 6 articles
Business
India: India is the location where Biopharmaceutical, the company providing the manufacturing services, is based and where the services will be provided.
Novo Nordisk: Novo Nordisk is outsourcing cartridge fill-finish manufacturing services to Biopharmaceutical, which could streamline its production and supply chain.
Jun 30, 2026 · 6 articles
Business
India: Domestic market; semaglutide supplies unavailable in India until late October, affecting local availability.
Novo Nordisk: Novo Nordisk is the originator of semaglutide; the delay does not directly affect its products but may reduce competition in the short term.
Jul 09, 2026 · 23 articles
Business
Novo Nordisk: Novo Nordisk partnered with Emcure Pharma to expand the distribution and marketing of its weight-loss drug semaglutide in India under the brand Poviztra, aiming to reach a wider population.
Nov 10, 2025 · 6 articles
ERGEN INTELLIGENCE
Explore this relationship live
Track how India and Novo Nordisk interact across events, view sentiment trends, and discover connected entities.
Open Dashboard